Biogen Slashes Annual Profit Forecast on Acquisition Charges
BIIB sits 55% above its 52-week low of $115.25.
Summary
Biogen has cut its full-year adjusted profit forecast for 2026, revising the expected range to $14.25-$15.25 per share from its previous guidance of $15.25-$16.25 per share. This reduction is primarily attributed to acquisition-related charges, specifically following the $5.6 billion buyout of Apellis Pharmaceuticals. While the company reported better-than-expected first-quarter earnings and sales for its Alzheimer's drug Leqembi and other treatments, the lowered forward-looking guidance signals a material impact on future profitability. A reduction in annual profit guidance is a significant negative development for investors, indicating a lower expected earnings trajectory despite strong current performance. Investors will closely monitor the integration of the Apellis acquisition and any further updates on its financial impact.
At the time of this announcement, BIIB was trading at $179.02 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $26.9B. The 52-week trading range was $115.25 to $202.41. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Reuters.